Methods Inf Med 1984; 23(01): 1-3
DOI: 10.1055/s-0038-1635321
Editorial
Schattauer GmbH

Medical Technology Assessment: An Emerging Evaluation Methodology

M. F. Collen
Further Information

Publication History

Publication Date:
17 February 2018 (online)

 

 
  • References

  • 1 Arnstein S. R.. Technology Assessment: Opportunities and Obstacles. IEEE Trans. Syst. Man Cybern. SMC 1977; 7: 571-582.
  • 2 Banta D. H., Behney C. J., Willems J. S.. Costs and their Evaluation. In Banta D. H.. et al. Toward Rational Technology in Medicine.; New York: Springer; 1981
  • 3 Berk A. A., Chalmers T. C. Cost and Efficacy of the Subsitution of Ambulatory for Inpatient Care. New Engl. J. Med 1981; 304: 393-397.
  • 4 Bunker J. P., Barnes B. J., Mosteller F.. Costs, Risks, and Benefits of Surgery. New York: Oxford Univ. Press; 1977
  • 5 Collen M. F.. A Case Study of Mammography. In Medical Technology and the Health Care System: A Study of the Diffusion of Equipment-Embodied Technology.. Washington, D. C: National Academy of Sciences; 1979
  • 6 Collen M. F.. A Study of Multiphasic Health Testing. In Medical Technology and the Health Care System: A Study of the Diffusion of Equipment-Embodied Technology.. Washington, D. C: National Academy of Sciences; 1979
  • 7 Collen M. F.. Cost-Effectiveness of Automated Laboratory Testing. In Young D. S.. et al. (Eds) Clinician and Chemist. Proc. First A. O. Beckman Conf. in Clinical Chemistry.. Washington, D. C: Amer. Ass. Clin. Chem.; 1979
  • 8 Collen M. F.. A Guideline Matrix for Technological System Evaluation. J. med. Syst 1979; 2: 249-254.
  • 9 Collen M. F.. Utilization of Diagnostic X-Ray Examinations. HHS Pub. FDA. 83-8208. Washington, D. C: US Government Printing Office; 1983
  • 10 Collen M. F., Dales L. G., Friedman G. D., Flagle C. D., Feldman R., Siegelaub A. B.. Multiphasic Health Checkup Evaluation Study. 4. Preliminary Cost Benefit Analysis for Middle-Aged Men. Prev. Med 1973; 2: 236-246.
  • 11 Collen M. F., Feldman R., Siegelaub A. B., Crawford D.. Dollar Cost per Positive Test for Automated Multiphasic Screening. New Engl. J. Med 1970; 283: 459-463.
  • 12 Collen M. F., Garfield S. R., Richart R. H., Duncan J. H., Feldman R.. Cost Analyses of Alternative Health Examination Modes. Arch. intern. Med 1977; 137: 73-79.
  • 13 Cooper B. S., Rice D. P.. The Economic Cost of Illness Revisited. Soc. Secur. Bull 1976; 39: 21-36.
  • 14 Drazen E., Metzger J.. Methods for Evaluating Costs of Automated Hospital Information Systems. DHHS Pub. No. (PHS) 81-3283. July 1981;
  • 15 Eddy D. M.. Screening for Cancer: Theory, Analysis and Design. Englewood Cliffs. Prentice-Hall 1980
  • 16 Klarman H. E.. Application of Cost-Benefit Analysis to Health Systems Technology. In Collen M. F.. (Edit.) Technology and Health Care Systems in the 1980’s. DHEW Pub. (HMS) 73-3016. 1973;
  • 17 McNeil B. J.. Pitfalls in and Requirements for Evaluations of Diagnostic Technologies. In Medical Technology, Urban Institute Conference. DHEW Pub. No. (PHS) 79-3254. Sept. 1979;
  • 18 Office of Technology Assessment, US Congress: Assessing the Efficacy and Safety of Medical Technologies. GPO Stock No. 052003-00593-0. Washington, D. C: US Government Printing Office; 1978
  • 19 Office of Technology Assessment, US Congress: The Implications of Cost—Effectiveness Analysis of Medical Technology. GPO Stock No. 052. 003-0765-7. Washington, D. C: US Government Printing Office; 1980
  • 20 Office of Technology Assessment, US Congress: Background Paper No. 3: The Efficacy and Cost Effectiveness of Psychotherapy. GPO Stock No. 052. 003-00783-5. Washington, D. C: US Government Printing Office; 1980
  • 21 Office of Technology Assessment, US Congress: Background Paper No. 2: Case Study No. 4: Cost Effectiveness of Automated Multichannel Chemistry Analyzers. Washington, D. C: US Government Printing Office; 1981
  • 22 Office of Technology Assessment, US Congress: Background Paper No. 2: Case Study No. 6: The Cost Effectiveness of Bone Marrow Transplant Therapy and its Policy Implications. Washington, D. C: US Government Printing Office; 1981
  • 23 Office of Technology Assessment, US Congress: Strategies for Medical Technology Assessment. GPO Stock No. 052-003-008-87-4 Washington, D. C: US Government Printing Office; 1982
  • 24 Patrick K. M., Woolley R.. A Cost-Benefit Analysis of Immunization for Pneumococcal Pneumonia. J. Amer. med. Ass 1981; 245: 473-477.
  • 25 Richart R. H.. Evaluation of a Hospital Computer System. In Collen M. F.. (Edit.) Hospital Computer Systems, pp. 341-417. New York: Wiley; 1974
  • 26 Stange P., Summer A. T.. Predicting Treatment Costs and Life Expectancy for End-Stage Renal Disease. New Engl. J. Med 1978; 298: 372-378.
  • 27 Willems J. S., Sanders R., Riddiough A., Bell C. Cost-Effectiveness of Vaccination against Pneumococcal Pneumonia. New Engl. J. Med 1980; 303: 553-559.